bluebird bio, Inc. Form 4 May 06, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Finer Mitchell H.			2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE]	5. Relationship of Reporting Person(s) to Issuer		
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction	(Check all applicable)		
			(Month/Day/Year)	Director 10% Owner		
C/O BLUEBIRD BIO, INC., 150 SECOND STREET			05/04/2015	X Officer (give title Other (specify below) Chief Scientific Officer		
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person		
CAMBRIDGE, MA 02141				Form filed by More than One Reporting		

(City)	(State)	(Zip) Tak	ole I - Non-	-Derivative	e Secu	rities Acquire	ed, Disposed of, o	or Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit on Disposed (Instr. 3, 4)	of (D) 4 and 5 (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/04/2015		M M	815	(D)	\$ 2.0864	815	D	
Common Stock	05/04/2015		M	14,185	A	\$ 5.5004	15,000	D	
Common Stock	05/04/2015		S(1)	6,886	D	\$ 131.269 (2)	8,114	D	
Common Stock	05/04/2015		S(1)	5,124	D	\$ 131.9411 (3)	2,990	D	
Common Stock	05/04/2015		S <u>(1)</u>	2,990	D	\$ 132.965 (4)	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and Underlying (Instr. 3 and	Securities	3 (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.0864	05/04/2015		M	266	<u>(5)</u>	07/13/2021	Common Stock	266	
Stock Option (right to buy)	\$ 2.0864	05/04/2015		M	549	<u>(6)</u>	06/04/2022	Common Stock	549	
Stock Option (right to buy)	\$ 5.5004	05/04/2015		M	14,185	<u>(7)</u>	01/16/2023	Common Stock	14,185	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			

Date

Finer Mitchell H. C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE, MA 02141

**Signature of Reporting Person

Chief Scientific Officer

Signatures

/s/ Jason F. Cole, Attorney-in-Fact 05/06/2015

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2014.
- The range of prices for the transaction reported on this line was \$130.50 to \$131.50. The average weighted price was \$131.2690. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was \$131.51 to \$132.50. The average weighted price was \$131.9411. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
 - The range of prices for the transaction reported on this line was \$132.75 to \$133.27. The average weighted price was \$132.9650. The
- (4) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (5) This option vests at a rate of twenty-five percent (25%) on April 15, 2012 and in 36 equal monthly installments thereafter.
- (6) This option vests at a rate of twenty-five percent (25%) on May 1, 2013 and in 36 equal monthly installments thereafter.
- This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met (7) as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.